mRNA-1083

BIOLOGICAL4 trials

Sponsors

ModernaTX, Inc.

Conditions

COVID-19InfluenzaSARS-CoV-2

Phase 1

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

CompletedNCT05827926

ModernaTX, Inc.Influenza, SARS-CoV-2

Start: 2023-04-14End: 2024-12-03Updated: 2025-12-23

Phase 2

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

CompletedNCT06508320

ModernaTX, Inc.Influenza, SARS-CoV-2

Start: 2024-07-15End: 2025-09-25Updated: 2025-10-14

Phase 3

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

CompletedNCT06097273

ModernaTX, Inc.Influenza, SARS-CoV-2

Start: 2023-10-19End: 2024-05-28Updated: 2025-07-01

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

CompletedNCT06694389

ModernaTX, Inc.COVID-19, Influenza

Start: 2024-11-18End: 2025-11-17Updated: 2025-12-02

Related Papers

Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan.

2026-07-30

Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years

Figshare2026-05-29

Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years

Figshare2026-05-29

Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.

2026-05-29

Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years

JAMA2025-05-0717 citations

Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study

Frontiers in Immunology2025-04-105 citations

mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial.

2025-03-186 citations